Physician profile

Allison Rose Taskin

Acute Care (Nurse Practitioner) · Lincoln, RI

NPI 1730785189

$3,201.50

in general payments reported to CMS, 2019-2025

21 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Redhill Biopharma INC. $408.81 2021-2022
Collegium Pharmaceutical, INC. $364.10 2021-2022
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $333.07 2021-2022
Nevro Corp. $309.18 2021-2022
Biodelivery Sciences International, INC. $283.32 2021
Abbvie INC. $282.00 2021-2022
Scilex Pharmaceuticals INC. $212.08 2021-2022
Biohaven Pharmaceutical Holding Company LTD. $137.64 2022
Biohaven Pharmaceuticals, INC. $133.96 2021
Teva Pharmaceuticals USA, INC. $122.07 2021-2022
Hikma Pharmaceuticals USA $121.16 2021-2022
Grt US Holding, INC. $111.64 2022
Indivior INC. $93.51 2021
Lilly USA, LLC $70.88 2021
Bioventus LLC $62.72 2022
Show all 21 companies
CompanyGeneral paymentsYearsTop products
Electronic Waveform Lab, INC. $44.63 2022
Almatica Pharma LLC $35.55 2021
Relievant Medsystems, INC. $22.32 2021
Novartis Pharmaceuticals Corporation $19.83 2021
Depuy Synthes Sales INC. $18.90 2021
Ultragenyx Pharmaceutical INC. $14.13 2022

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Allison Rose Taskin

$3,201.50

in general payments reported 2019-2025

Years
2021-2022
Top company
Redhill Biopharma INC.

https://glasscript.com/doctor/10987606/allison-rose-taskin

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.